表紙
市場調查報告書

細胞治療藥製造市場

Cell Therapy Manufacturing Market (3rd Edition), 2019-2030

出版商 ROOTS ANALYSIS 商品編碼 462554
出版日期 內容資訊 英文 502 Pages
商品交期: 最快1-2個工作天內
價格
細胞治療藥製造市場 Cell Therapy Manufacturing Market (3rd Edition), 2019-2030
出版日期: 2020年01月31日內容資訊: 英文 502 Pages
簡介

細胞治療藥製造市場,由於現有的製造設備的擴張和新的專用設施的建設,預計中、長期性地持續穩定成長。技術的進步,成為成長的主要成功因素。

本報告提供細胞治療藥製造市場相關調查分析,目前的市場情勢和未來預測相關的系統性資訊。

第1章 序文

第2章 摘要整理

第3章 簡介

第4章 市場概要

  • 概要
  • 綜合市場形勢
  • 物流服務供應商所扮演的角色

第5章 藍圖:克服現有的課題的潛在策略

  • 概要
  • 美國的藍圖
  • 其他地區的藍圖

第6章 細胞治療藥製造:內部廠商

  • 概要
  • Argos Therapeutics
  • Bavarian Nordic
  • Cytori Therapeutics
  • Juno Therapeutics
  • MEDIPOST
  • SOTIO
  • Stemedica Cell Technologies

第7章 細胞治療藥製造:產業企業

  • 概要
  • Cell and Gene Therapy Catapult
  • CELLforCURE
  • Lonza
  • PharmaCell
  • PCT
  • Roslin Cell Therapies
  • Waisman Biomanufacturing

第8章 細胞治療藥製造:產業外企業

  • 概要
  • Center for Cell and Gene Therapy, Baylor College of Medicine (美國)
  • Centre for Cell Manufacturing Ireland, National University of Ireland (愛爾蘭)
  • Clinical Cell and Vaccine Production Facility, University of Pennsylvania (美國)
  • Guy's And St. Thomas' GMP Facility, Guy's Hospital (英國)
  • Newcastle Cellular Therapies Facility, Newcastle University (英國)
  • Rayne Cell Therapy Suite, King's College London (英國)
  • Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre of Regenerative Medicine (英國)
  • Laboratory of Cell and Gene Medicine, Stanford University (美國)

第9章 NPO所扮演的角色

  • 概要
  • NPO的清單
  • 國際團體

第10章 最近的發展

  • 概要
  • 聯盟/契約模式
  • 聯盟的清單
  • 夥伴關係分析

第11章 市場規模與預測

  • 情形和背景
  • 預測手法
  • 細胞治療藥製造市場
  • 各地區分析

第12章 SWOT分析

  • 概要
  • 優勢
  • 弱點
  • 機會
  • 威脅

第13章 結論

第14章 調查分析

第15章 採訪

第16章 附錄1

第17章 附錄2

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Overview

Till date, more than 20 cell-based therapies have been approved (recent examples include Zynteglo® (2019), Alofisel® (2018), YESCARTA® (2017) and Kymriah® (2017)), while over 500 product candidates are under development. In fact, there are over 1,000 active clinical studies of cell therapies, worldwide. Over the last few years, such therapies have garnered significant attention within the biopharmaceutical industry. Several companies and venture capital funds / investors have already invested a lot of capital towards the development and commercialization of this emerging class of therapeutics. Despite the optimism, the growth in this domain is still hindered by various development and manufacturing related challenges, primarily due to the limited availability of expertise and infrastructure to produce cell-based therapies, such as CAR-T cell therapies. The growing number of product development initiatives in this domain, coupled to the fact that there are multiple marketed products, have led to a substantial rise in the overall cell therapy manufacturing demand. As a result, developers have turned to contract manufacturing organizations (CMOs) to fulfil their cell therapy development and production requirements.

A wide array of industry players, including well-established companies, mid-sized firms and start-ups, as well as academic institutes, are contributing towards fulfilling the aforementioned demand, offering GMP grade manufacturing services for cell therapies. In addition to cell therapy manufacturing companies, there are several other players that claim to have developed novel technology solutions, aimed at improving the existing cell therapy manufacturing process. Many CMOs are also actively expanding their cell therapy manufacturing capacity either through collaborations or acquisitions, in order to offer a wide range of services to their respective clients. As a result of the ongoing efforts aimed at mitigating the existing challenges in this domain, the cell therapy manufacturing market is expected to witness significant growth in mid-long term.

Scope of the Report

The "Cell Therapy Manufacturing Market (3rd Edition), 2019-2030" features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing. It focuses on both contract manufacturers, as well as developers with in-house manufacturing facilities, offering in-depth analyses of the various business entities that are engaged in this domain, across different global regions. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of companies that are engaged in the manufacturing of cell-based therapies, including information on the type of cells manufactured (including immune cells (including T cells, dendritic cells, NK cells), stem cells (including adult stem cells, human embryonic stem cells and induced pluripotent stem cells) and others), source of cells (autologous and allogeneic), scale of manufacturing, type of cell cultures (adherent and suspension), purpose of production (fulfilling in-house requirements and contract services), manufacturing capabilities / services offered (including R&D, cell culture development, quality testing, packaging, labelling, cell banking, cryopreservation, fill / finish services, and regulatory affairs management), location of headquarters and location of their respective manufacturing facilities.
  • An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective cell therapy manufacturing capabilities, over the period 2015-2019 (till October), taking into consideration parameters, such as year of expansion, type of cells, scale of operation, purpose of expansion (facility expansion and new facility), location of manufacturing facility, and most active players (in terms of number of expansion initiatives undertaken).
  • An analysis of the recent partnerships focused on the manufacturing of cell-based therapies, which have been established in the period 2014-2019 (till November), based on various relevant parameters, such as the year of agreement, type of partnership, type of cells, and scale of operation (preclinical, clinical and commercial).
  • Informed estimates of the annual commercial and clinical demand for cell therapies (in terms of number of cells produced and area dedicated to manufacturing), which were further analyzed based on type of cells.
  • An estimate of the overall, installed capacity for manufacturing cell-based therapies based on information reported by industry stakeholders in the public domain, highlighting the distribution of the available capacity on the basis of scale of operation (clinical and commercial), size of the organization (small, mid-sized and large firms) and key geographical regions (North America, EU and Asia Pacific).
  • An in-depth analysis of cell therapy manufacturers using three versatile representations, namely [A] a three dimensional grid analysis, presenting the distribution of companies on the basis of type of cells manufactured, scale of operation and purpose of production, [B] a logo landscape based on the type of cells manufactured, geographical location of manufacturer (North America, Europe and Asia Pacific) and type and size of organization (non-industry players, and small, mid-sized and large companies), and [C] a schematic world map representation, highlighting the geographical locations of cell therapy manufacturing facilities of both industry and non-industry stakeholders.
  • A detailed analysis of the various factors that are likely to influence the pricing of cell-based therapies, featuring different models / approaches that may be adopted by manufacturers while deciding the prices of their proprietary offerings.
  • An elaborate discussion on the role of automation technologies in improving current manufacturing methods, along with a comparative (qualitive) analysis of cost differences between manual and automated processes.
  • A qualitative analysis, highlighting the various factors that need to be taken into consideration by cell therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
  • A discussion on cell therapy manufacturing regulations across various geographies, including the North America (focusing on the US), Europe and Asia (focusing on Japan), featuring an analysis of the diverse certifications / accreditations awarded to manufacturing facilities by important regulatory bodies across the globe.
  • Elaborate profiles of key players (industry and non-industry) that offer contract manufacturing services for cell-based therapies; each profile includes an overview of the company / organization, information on its manufacturing facilities, service portfolio details, recent partnerships and an informed future outlook.
  • A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry's evolution, under a comprehensive SWOT framework, which includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall market dynamics.
  • Insights generated in a market-wide survey, featuring inputs solicited from experts who are directly and indirectly involved in the development and / or manufacturing of cell-based therapies.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the cell therapy manufacturing market. Based on parameters, such as number of ongoing / planned clinical studies, cell therapy manufacturing costs, target patient population, and anticipated adoption of such products, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and mid to long term, for the period 2019-2030. In addition, to account for the uncertainties associated with the manufacturing of cell-based therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The study includes detailed transcripts of discussions held with the following individuals:

  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Tim Oldham (Chief Executive Officer, Cell Therapies)
  • Gerard MJ Bos (Chief Executive Officer, CiMaas)
  • Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
  • Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
  • Arik Hasson (Executive VP Research and Development, Kadimastem)
  • Gilles Devillers (General Manager, Bio Elpida)
  • Arnaud Deladeriere (Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy)
  • Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
  • Fiona Bellot (Business Development Manager, Roslin CT)
  • Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, Yposkesi)
  • David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the cell-based therapy manufacturing market in the short to mid-term, and long term.

Chapter 3 provides a general introduction to cell-based therapies and ATMPs. It includes a detailed discussion on the manufacturing process of cell-based therapies, and associated challenges and applications of currently available cell therapies. It also provides information on the different manufacturing models (centralized and decentralized) that are being used for the production of cell-based therapies, along with a discussion on their respective advantages and disadvantages. Further, it features details related to the scalability of cell-based therapies. The chapter also includes a brief overview on the role of automation and the need for effective supply chain management for cell-based therapies.

Chapter 4 features a detailed list of all the industry, as well as non-industry players that are actively involved in the manufacturing of cell-based therapies. It provides information on the location of their manufacturing facilities, scale of manufacturing, type of cells manufactured (immune cells (such as T cells, dendritic cells, NK cells), stem cells (such as adult stem cells, human embryonic stem cells and induced pluripotent stem cells) and others), purpose of production (fulfilling in-house requirements / as a contract service provider), source of cells (autologous / allogeneic), manufacturing capabilities / services offered (such as R&D, cell culture development, testing, packaging, labelling, cell banking, cryopreservation, fill/ finish services, regulatory services).

Chapter 5 features a detailed discussion on the regulatory landscape related to cell therapies across various geographies, such as the US, Europe and Japan. Further, it presents an analysis of the manufacturing facilities on basis of the certifications awarded (for manufacturing cell-based therapies) to individual sites by various regulatory bodies across the globe.

Chapter 6 describes the strategies that are likely to be adopted to accelerate the translation of cell-based therapies from laboratory to clinics. It provides details on roadmaps published by different organizations located across various geographies, specifically in the US.

Chapter 7 discusses the role of automation technologies in optimization of current manufacturing practices with the use of closed and single use systems. Further, it features a roadmap that provides information on the steps to develop automation devices, supported by two case studies. It also presents a qualitive analysis on the cost incurred while manufacturing cell-based therapies using manual versus automated manufacturing approaches. In addition, it features a list of organizations that offer automated technologies for manufacturing operations or provide services to therapy developers to automate their production processes.

Chapter 8 features detailed profiles of industry players that offer contract manufacturing services for cell therapies at the clinical and / or commercial scales. Each profile provides a brief overview of the company, details on its manufacturing capabilities and facilities, recent partnerships and an informed future outlook.

Chapter 9 features profiles of non-industry players that offer contract manufacturing services for cell therapies. Each profile provides a brief overview of the organization, and details on its service portfolio and manufacturing facilities.

Chapter 10 discusses the role of non-profit organizations in this domain. It provides a list of organizations that are actively involved in the development and production of cell-based therapies, across different global regions. Further, it includes profiles of organizations that provide financial and / or technological support to cell therapy manufacturers and developers. Additionally, the chapter provides information on various international / national societies that help in disseminating knowledge about the advancement of these therapies to the general community.

Chapter 11 features an analysis of the various partnerships and collaborations that have been inked amongst players engaged in this domain, between 2014-2019. It includes a brief description on the various types of partnership models (which include manufacturing agreements, manufacturing process development agreements, licensing agreements, additional services agreements, acquisitions, joint ventures, service alliances and others) that are employed by stakeholders in this market, and an analysis on the trend of partnerships inked since 2014. It also includes analyses based on year of agreement, type of partnership, scale of operation, types of services offered and types of cells manufactured. Further, the chapter features a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 12 presents detailed analysis on the expansions that have taken place in the cell therapy manufacturing industry, since 2014. It includes information on expansions carried out for increasing existing capabilities, as well as those intended for setting-up of new facilities by manufacturers engaged in this domain. The expansion instances that we came across were analyzed based on various parameters, including year of expansion, type of expansion (capacity expansion and new facility), geographical location of the facility, scale of operation (as mentioned in the expansion terms), type of capability (research and manufacturing), type of cells (CAR-T cells, TCR cells, TIL cells, NK cells, dendritic cells and stem cells).

Chapter 13 features a comprehensive analysis of the overall installed capacity of cell-based therapy manufacturers. The analysis is based on meticulous data collection of reported capacities, via both secondary and primary research, of various small, mid-sized and large companies, and non-industry players distributed across their respective facilities. The results of this analysis were used to establish an informed opinion on the cell-based therapy production capabilities of organizations across different types of organization (industry and non-industry), scale of operation (clinical and commercial), geographies (North America, EU, Asia Pacific and the rest of the world) and size of the organization (small, mid-sized and large organizations).

Chapter 14 features a detailed analysis of the annual demand for cell therapies (in terms of number of cells produced and area dedicated to manufacturing), considering various relevant parameters, such as target patient population, dosing frequency and dose strength of the approved cell therapies, as well as those therapies that are currently being evaluated in clinical trials. The demand analysis has been segmented across different types of cell therapies (including CAR-T cells, TCR cells, TIL cells, NK cells, dendritic cells and stem cells), scales of operation (clinical and commercial) and regions (North America, Europe and Asia Pacific).

Chapter 15 highlights our views on the various factors, including manufacturing costs, that may be taken into consideration while pricing cell-based therapies. It features discussions on different pricing models / approaches, which a manufacturer may choose to adopt to decide the price of its proprietary products.

Chapter 16 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by cell therapy developers while deciding whether to manufacture their respective products in-house or engage the services of a CMOs.

Chapter 17 presents a comprehensive market forecast analysis, highlighting the likely growth of the cell therapy manufacturing market till the year 2030. We have segregated the opportunity by type of cell therapy (T-cell immunotherapies, dendritic cell-based therapies, NK cell therapies, stem cell therapies and other ATMPs), scale of operation (clinical and commercial), source of cells (autologous and allogeneic), purpose of production (in-house and contract services) and geography (North America, EU and Asia Pacific).

Chapter 18 presents a collection of key insights derived from the study. It includes a grid analysis, highlighting the distribution of cell-based therapy manufacturers on the basis of type of cells manufactured, scale of production and purpose of manufacturing (fulfilling in-house requirement / contract service provider). In addition, it consists of two logo landscapes, representing the distribution of cell-based therapy manufacturers based on the type of cells manufactured (immune cells and stem cells), geographical regions (North America, EU and Asia Pacific) and the type / size of organization (non-industry, small, mid-sized and large companies). The chapter also comprises of two schematic world map representations to highlight the locations of various cell-based therapy manufacturing facilities across different continents.

Chapter 19 provides a discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall industry.

Chapter 20 summarizes the entire report. It provides the key takeaways and presents our independent opinion of the cell therapy manufacturing market, based on the research and analysis described in the previous chapters.

Chapter 21 presents insights from the survey conducted for this study. We invited over 100 stakeholders involved in the development and / or manufacturing of different types of cell therapies. The participants, who were primarily Director / CXO level representatives of their respective companies, helped us develop a deeper understanding on the nature of their services and the associated commercial potential.

Chapter 22 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), Tim Oldham (Chief Executive Officer, Cell Therapies), Gerard MJ Bos (Chief Executive Officer, CiMaas), Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics), Arik Hasson (Executive VP Research and Development, Kadimastem), Gilles Devillers (General Manager, Bio Elpida), Arnaud Deladeriere (Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Fiona Bellot (Business Development Manager, Roslin CT), Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, Yposkesi) and David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota).

Chapter 23 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 24 is an appendix that provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Context and Background
  • 3.2. Introduction to Cell Therapies
    • 3.2.1. Comparison of Cell Therapies and Other Biotechnology Products
    • 3.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
    • 3.2.3. Current Market Landscape of ATMPs
  • 3.3. Overview of Cell Therapy Manufacturing
  • 3.4. Cell Therapy Manufacturing Models
    • 3.4.1. Centralized Manufacturing
    • 3.4.2. Decentralized Manufacturing
  • 3.5. Scalability of Cell Therapy Manufacturing
    • 3.5.1. Scale-up
    • 3.5.2. Scale-out
  • 3.6. Types of Cell Therapy Manufacturers
  • 3.7. Key Manufacturing-related Challenges
  • 3.8. Factors Influencing Cell Therapy Manufacturing
  • 3.9. Automating Cell Therapy Manufacturing
  • 3.10. Cell Therapy Manufacturing Supply Chain
  • 3.11. Future Perspectives

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Cell Therapy Manufacturers (Industry Players): Overall Market Landscape
    • 4.2.1. Analysis by Location of Headquarters
    • 4.2.2. Analysis by Location of Manufacturing Facility
    • 4.2.3. Analysis by Type of Cells Manufactured
    • 4.2.4. Analysis by Source of Cells
    • 4.2.5. Analysis by Scale of Operation
    • 4.2.6. Analysis by Type of Cell Culture
    • 4.2.7. Analysis by Purpose of Production
    • 4.2.8. Analysis by Manufacturing Capabilities / Services
  • 4.3. Cell Therapy Manufacturers (Non-Industry Players): Overall Market Landscape
    • 4.3.1. Analysis by Location of Headquarters
    • 4.3.2. Analysis by Location of Manufacturing Facility
    • 4.3.3. Analysis by Type of Cells Manufactured
    • 4.3.4. Analysis by Source of Cells
    • 4.3.5. Analysis by Scale of Operation
    • 4.3.6. Analysis by Type of Cell Culture
    • 4.3.7. Analysis by Purpose of Production
    • 4.3.8. Analysis by Manufacturing Capabilities / Services
  • 4.4. Cell Therapy Manufacturing: Role of Logistics Service Providers

5. REGULATORY LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Current Scenario
    • 5.2.1. Regulatory Guidelines in the US
    • 5.2.2. Regulatory Guidelines in Europe
    • 5.2.3. Regulatory Guidelines in Japan
    • 5.2.4. Conditional Approvals
  • 5.3. Regulatory Accreditations for Cell Therapy Manufacturing
    • 5.3.1. Facilities Approved by Regulators to Manufacture Cell Therapies
  • 5.4. Summary of Guidelines for Clinical-Stage Manufacturing of Cell Therapies
  • 5.5. Existing Challenges to Clinical-Stage Manufacturing
    • 5.5.1. Variability in Regulatory Guidelines across Different Geographies
  • 5.6. Conclusion

6. ROADMAPS FOR OVERCOMING EXISTING CHALLENGES

  • 6.1. Chapter Overview
  • 6.2. Roadmap for the US
    • 6.2.1. Cell Processing
    • 6.2.2. Cell Preservation, Distribution and Handling
    • 6.2.3. Process Automation and Data Analytics
    • 6.2.4. Process Monitoring and Quality Control
    • 6.2.5. Standardization and Regulatory Support
    • 6.2.6. Workforce Development
    • 6.2.7. Supply Chain and Logistics
  • 6.3. Roadmaps for Other Geographies
    • 6.3.1. Europe
    • 6.3.2. Asia Pacific

7. AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING

  • 7.1. Chapter Overview
  • 7.2. Automation of Cell Therapy Manufacturing Processes
    • 7.2.1. Closed Systems
    • 7.2.2. Single-use Systems
    • 7.2.3. Modular Systems
  • 7.3. Case Studies
    • 7.3.1. Roadmap to Developing an Automated Cell Manufacturing / Processing Device
    • 7.3.2. Automating Cell Therapy Manufacturing
  • 7.4. GMP-in-a-Box
  • 7.5. List of Automation Service Providers
  • 7.6. Comparative Analysis of Manual and Automated Processes
  • 7.7. Concluding Remarks

8. PROFILES: INDUSTRY PLAYERS

  • 8.1. Chapter Overview
  • 8.2. Service Providers in the US
    • 8.2.1 Cognate BioServices
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Service Portfolio
      • 8.2.1.3. Manufacturing Capabilities
      • 8.2.1.4. Partnerships
      • 8.2.1.5. Future Outlook
    • 8.2.2. FUJIFILM Cellular Dynamics
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Service Portfolio
      • 8.2.2.3. Manufacturing Capabilities
      • 8.2.2.4. Partnerships
      • 8.2.2.5. Future Outlook
    • 8.2.3. KBI Biopharma
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Service Portfolio
      • 8.2.3.3. Manufacturing Capabilities
      • 8.2.3.4. Partnerships
      • 8.2.3.5. Future Outlook
    • 8.2.4. Hitachi Chemical Advanced Therapeutics Solutions
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Service Portfolio
      • 8.2.4.3. Manufacturing Capabilities
      • 8.2.4.4. Partnerships
      • 8.2.4.5. Future Outlook
    • 8.2.5. Waisman Biomanufacturing
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Service Portfolio
      • 8.2.5.3. Manufacturing Capabilities
      • 8.2.5.4. Partnerships
      • 8.2.5.5. Future Outlook
  • 8.3. Service Providers in Europe
    • 8.3.1. BioNTech Innovative Manufacturing Services
      • 8.3.1.1. Company Overview
      • 8.3.1.2. Service Portfolio
      • 8.3.1.3. Manufacturing Capabilities
      • 8.3.1.4. Partnerships
      • 8.3.1.5. Future Outlook
    • 8.3.2. Cell and Gene Therapy Catapult
      • 8.3.2.1. Company Overview
      • 8.3.2.2. Service Portfolio
      • 8.3.2.3. Manufacturing Capabilities
      • 8.3.2.4. Partnerships
      • 8.3.2.5. Future Outlook
    • 8.3.3. Lonza
      • 8.3.3.1. Company Overview
      • 8.3.3.2. Service Portfolio
      • 8.3.3.3. Manufacturing Capabilities
      • 8.3.3.4. Partnerships
      • 8.3.3.5. Future Outlook
    • 8.3.4. MaSTherCell
      • 8.3.4.1. Company Overview
      • 8.3.4.2. Service Portfolio
      • 8.3.4.3. Manufacturing Capabilities
      • 8.3.4.4. Partnerships
      • 8.3.4.5. Future Outlook
    • 8.3.5. Roslin Cell Therapies
      • 8.3.5.1. Company Overview
      • 8.3.5.2. Service Portfolio
      • 8.3.5.3. Manufacturing Capabilities
      • 8.3.5.4. Partnerships
      • 8.3.5.5. Future Outlook
  • 8.4. Service Providers in Asia Pacific
    • 8.4.1. Cell Therapies
      • 8.4.1.1. Company Overview
      • 8.4.1.2. Service Portfolio
      • 8.4.1.3. Manufacturing Capabilities
      • 8.4.1.4. Partnerships
      • 8.4.1.5. Future Outlook
    • 8.4.2. Japan Tissue Engineering (J-TEC)
      • 8.4.2.1. Company Overview
      • 8.4.2.2. Service Portfolio
      • 8.4.2.3. Manufacturing Capabilities
      • 8.4.2.4. Partnerships
      • 8.4.2.5. Future Outlook
    • 8.4.3. MEDINET
      • 8.4.3.1. Company Overview
      • 8.4.3.2. Service Portfolio
      • 8.4.3.3. Manufacturing Capabilities
      • 8.4.3.4. Partnerships
      • 8.4.3.5. Future Outlook
    • 8.4.4. Nikon CeLL innovation
      • 8.4.4.1. Company Overview
      • 8.4.4.2. Service Portfolio
      • 8.4.4.3. Manufacturing Capabilities
      • 8.4.4.4. Partnerships
      • 8.4.4.5. Future Outlook
    • 8.4.5. WuXi Advanced Therapies
      • 8.4.5.1. Company Overview
      • 8.4.5.2. Service Portfolio
      • 8.4.5.3. Manufacturing Capabilities
      • 8.4.5.4. Partnerships
      • 8.4.5.5. Future Outlook

9. PROFILES: NON-INDUSTRY PLAYERS

  • 9.1. Chapter Overview
  • 9.2. Center for Cell and Gene Therapy, Baylor College of Medicine
    • 9.2.1. Overview
    • 9.2.2. Operating Segments
    • 9.2.3. Service Portfolio
    • 9.2.4. Manufacturing Facilities and Capabilities
  • 9.3. Centre for Cell Manufacturing Ireland, National University of Ireland
    • 9.3.1. Overview
    • 9.3.2. Service Portfolio
    • 9.3.3. Manufacturing Facilities and Capabilities
  • 9.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania
    • 9.4.1. Overview
    • 9.4.2. Service Portfolio
    • 9.4.3. Manufacturing Facilities and Capabilities
  • 9.5. Guy's and St. Thomas' GMP Facility, Guy's Hospital
    • 9.5.1. Overview
    • 9.5.2. Service Portfolio
    • 9.5.3. Manufacturing Facilities and Capabilities
  • 9.6. Laboratory for Cell and Gene Medicine, Stanford University
    • 9.6.1. Overview
    • 9.6.2. Service Portfolio
    • 9.6.3. Manufacturing Facilities and Capabilities
  • 9.7. Molecular and Cellular Therapeutics, University of Minnesota
    • 9.7.1. Overview
    • 9.7.2. Service Portfolio
    • 9.7.3. Manufacturing Facilities and Capabilities
  • 9.8. Newcastle Cellular Therapies Facility, Newcastle University
    • 9.8.1. Overview
    • 9.8.2. Service Portfolio
    • 9.8.3. Manufacturing Facilities and Capabilities
  • 9.9. Rayne Cell Therapy Suite, King's College London
    • 9.9.1. Overview
    • 9.9.2. Manufacturing Facilities and Capabilities
  • 9.10. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
    • 9.10.1. Overview
    • 9.10.2. Manufacturing Facilities and Capabilities
  • 9.11. Sydney Cell and Gene Therapy
    • 9.11.1. Overview
    • 9.11.2. Manufacturing Facilities and Capabilities

10. ROLE OF NON-PROFIT ORGANIZATIONS

  • 10.1. Chapter Overview
  • 10.2. Cell Therapy Manufacturing Service Providers: Non-Profit Organizations
    • 10.2.1. CellCAN
    • 10.2.2. Cell Therapy Manufacturing Cooperative Research Center (CTM CRC)
    • 10.2.3. National Cell Manufacturing Consortium (NCMC)
    • 10.2.4. California Institute of Regenerative Medicine (CIRM)
  • 10.3. Cell Therapy Manufacturing: Affiliated International Societies

11. PARTNERSHIPS

  • 11.1. Chapter Overview
  • 11.2. Partnership Models
  • 11.3. Cell Therapy Manufacturing: List of Partnerships
    • 11.3.1. Analysis by Year of Partnership
    • 11.3.2. Analysis by Type of Partnership Model
    • 11.3.3. Analysis by Year and Type of Partnership Model
  • 11.4. Analysis by Type of Cells
  • 11.5. Analysis by Scale of Operation
  • 11.6. Geographical Analysis
    • 11.6.1. Continent-wise Distribution
    • 11.6.2. Country-wise Distribution
  • 11.7. Most Active Players: Analysis by Number of Partnerships
  • 11.8. Cell Therapy Manufacturing: List of Acquisitions
    • 11.8.1. Analysis by Year and Type of Cells
    • 11.8.2. Geographical Analysis
    • 11.8.3. Ownership Change Matrix

12. FACILITY EXPANSIONS

  • 12.1. Chapter Overview
  • 12.2. Cell Therapy Manufacturing: List of Expansions
    • 12.2.1. Cumulative Year-wise Distribution
    • 12.2.2. Analysis by Type of Cells
    • 12.2.3. Analysis by Scale of Operation
    • 12.2.3. Analysis by Purpose of Expansion
    • 12.2.4. Analysis by Location of Manufacturing Facility
    • 12.2.5. Analysis by Region and Purpose of Expansion

13. CAPACITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Key Assumptions and Methodology (Industry Players)
    • 13.2.1 Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
      • 13.2.1.1. Analysis by Size of Manufacturer
      • 13.2.1.2. Analysis by Scale of Operation
      • 13.2.1.3. Analysis by Location of Manufacturing Facility
    • 13.2.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
      • 13.2.2.1. Analysis by Size of Manufacturer
      • 13.2.2.2. Analysis by Scale of Operation
      • 13.2.2.3. Analysis by Location of Manufacturing Facility
  • 13.3. Key Assumptions and Methodology (Non-Industry Players)
    • 13.3.1. Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
      • 13.3.1.1. Analysis by Scale of Operation
      • 13.3.1.2. Analysis by Location of Manufacturing Facility
    • 13.3.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
      • 13.3.2.1. Analysis by Scale of Operation
      • 13.3.2.2. Analysis by Location of Manufacturing Facility
  • 13.4 Concluding Remarks

14. DEMAND ANALYSIS

  • 14.1 Chapter Overview
  • 14.2 Key Assumptions and Methodology
  • 14.3 Cell Therapy Manufacturing: Overall Annual Demand
    • 14.3.1. Analysis by Type of Cells
    • 14.3.2. Analysis by Scale of Operations
    • 14.3.3. Analysis by Geography

15. COST PRICE ANALYSIS

  • 15.1. Chapter Overview
  • 15.2. Factors Contributing to the High Price of Cell Therapies
  • 15.3. Pricing Models for Cell Therapies
    • 15.3.1. Based on Associated Costs for T-cell Therapies
    • 15.3.2. Based on Associated Costs for Stem Cell Therapies
    • 15.3.3. Based on Availability of Competing Products
    • 15.3.4. Based on Target Patient Segment
    • 15.3.5. Based on Opinions of Industry Experts
  • 15.4. Cell Therapy Cost Optimization
    • 15.4.1. Role of Cost of Goods Sold
    • 15.4.2. Role of Automation
    • 15.4.3. Role of Cell Therapy Contract Manufacturing Organizations
  • 15.5. Reimbursement-related Considerations for Cell Therapies
    • 15.5.1. Case Study: The National Institute for Health and Care Excellence's (NICE) Appraisal of CAR-T Therapies

16. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

  • 16.1. Chapter Overview
  • 16.2. Make versus Buy Decision Making: Analytical Output

17. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 17.1. Chapter Overview
  • 17.2. Scope of the Forecast
  • 17.3. Forecast Methodology
  • 17.4. Input Tables and Key Assumptions
  • 17.5. Overall Cell Therapy Manufacturing Market, 2019-2030
    • 17.5.1. Cell Therapy Manufacturing Market, 2019-2030: Distribution by Type of Cell Therapy
    • 17.5.2. Cell Therapy Manufacturing Market, 2019-2030: Distribution by Source of Cells
    • 17.5.3. Cell Therapy Manufacturing Market, 2019-2030: Distribution by Scale of Operation
    • 17.5.4. Cell Therapy Manufacturing Market, 2019-2030: Distribution by Purpose of Production
    • 17.5.5. Cell Therapy Manufacturing Market, 2019-2030: Geographical Distribution
  • 17.6. Market Opportunity in Commercial Scale Manufacturing of Cell-based Therapies
    • 17.6.1. Overall Commercial Scale Manufacturing Market for T-cell Therapies, 2019-2030
      • 17.6.1.1. Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, and TIL Therapy)
      • 17.6.1.2. Distribution by Source of Cells
      • 17.6.1.3. Geographical Distribution
    • 17.6.2. Overall Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2019-2030
      • 17.6.2.1. Distribution by Type of Therapy (Dendritic Cell Therapy, and Tumor Cell Therapy)
      • 17.6.2.2. Distribution by Source of Cells
      • 17.6.2.3. Geographical Distribution
    • 17.6.3. Overall Commercial Scale Manufacturing Market for NK Cell Therapies, 2019-2030
      • 17.6.3.1. Distribution by Source of Cells
      • 17.6.3.2. Geographical Distribution
    • 17.6.4. Overall Commercial Scale Manufacturing Market for Stem Cell Therapies, 2019-2030
      • 17.6.4.1. Distribution by Source of Cells
      • 17.6.4.2. Geographical Distribution
  • 17.7. Market Opportunity in Clinical Scale Manufacturing of Cell-based Therapies
    • 17.7.1. Overall Clinical Scale Manufacturing Market for T-cell Therapies, 2019-2030
      • 17.7.1.1. Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy and TIL Therapy)
      • 17.7.1.2. Distribution by Source of Cells
      • 17.7.1.3. Geographical Distribution
    • 17.7.2. Overall Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, 2019-2030
      • 17.7.2.1. Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy)
      • 17.7.2.2. Distribution by Source of Cells
      • 17.7.2.3. Geographical Distribution
    • 17.7.3. Overall Clinical Scale Manufacturing Market for NK Cell Therapies, 2019-2030
      • 17.7.3.1. Distribution by Source of Cells
      • 17.7.3.2. Geographical Distribution
    • 17.7.4. Overall Clinical Scale Manufacturing Market for Stem Cell Therapies, 2019-2030
      • 17.7.4.1. Distribution by Source of Cells
      • 17.7.4.2. Geographical Distribution

18. KEY INSIGHTS

  • 18.1. Chapter Overview
  • 18.2. Cell Therapy Manufacturers: Grid Analysis
  • 18.3. Cell Therapy Manufacturers: Logo Landscape by Type of Cell Therapy
    • 18.3.1. Logo Landscape: Immune Cell Manufacturers
    • 18.3.2. Logo Landscape: Stem Cell Manufacturers
  • 18.4. Cell Therapy Manufacturers: World Map Representation of Location of Manufacturing Facility
    • 18.4.1. Industry Players
    • 18.4.2. Non-Industry Players

19. SWOT ANALYSIS

  • 19.1. Chapter Overview
  • 19.2. Strengths
  • 19.3. Weaknesses
  • 19.4. Opportunities
  • 19.5. Threats
  • 19.6. Comparison of SWOT Factors
    • 19.6.1. Concluding Remarks

20. CONCLUSION

  • 20.1. Chapter Overview
  • 20.2. Key Takeaways

21. SURVEY ANALYSIS

  • 21.1. Chapter Overview
  • 21.2. Seniority Level of Respondents
  • 21.3. Type of Cell Therapy
  • 21.4. Scale of Operation
  • 21.5. Source of Cells
  • 21.6. Type of Cell Culture System
  • 21.7. Availability of Fill / Finish Services

22. INTERVIEW TRANSCRIPTS

  • 22.1. Chapter Overview
  • 22.2. Lion TCR
    • 22.2.1. Company Overview
    • 22.2.2. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
  • 22.3. Cell Therapies
    • 22.3.1. Company Overview
    • 22.3.2. Interview Transcript: Tim Oldham, Chief Executive Officer
  • 22.4. CiMaas
    • 22.4.1. Company Overview
    • 22.4.2. Interview Transcript: Gerard MJ Bos, Chief Executive Officer
  • 22.5. Gracell Biotechnologies
    • 22.5.1. Company Overview
    • 22.5.2. Interview Transcript: Wei (William) Cao, Chief Executive Officer
  • 22.6. Glycostem Therapeutics
    • 22.6.1. Company Overview
    • 22.6.2. Interview Transcript: Troels Jordansen, Chief Executive Officer
  • 22.7. Kadimastem
    • 22.7.1. Company Overview
    • 22.7.2. Interview Transcript: Arik Hasson, Executive VP Research and Development
  • 22.8. Bio Elpida
    • 22.8.1. Company Overview
    • 22.8.2. Interview Transcript: Gilles Devillers, General Manager
  • 22.9. Center for Commercialization of Cancer Immunotherapy / C3i
    • 22.9.1. Company Overview
    • 22.9.2. Interview Transcript: Arnaud Deladeriere, Manager, Business Development & Operations-cGMP Manufacturing Unit
  • 22.10. Waisman Biomanufacturing
    • 22.10.1. Company Overview
    • 22.10.2. Interview Transcript: Brian Dattilo, Manager of Business Development
  • 22.11. RoslinCT
    • 22.11.1. Company Overview
    • 22.11.2. Interview Transcript: Fiona Bellot, Business Development Manager
  • 22.12. Yposkesi
    • 22.12.1. Company Overview
    • 22.12.2. Interview Transcript: Mathilde Girard, Department Leader, Cell Therapy Innovation and Development
  • 22.13. University of Minnesota
    • 22.13.1. Organization Overview
    • 22.13.2. Interview Transcript: David Mckenna, Professor and American Red Cross Chair in Transfusion Medicine

23. APPENDIX 1: TABULATED DATA

24. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figuers

  • Figure 3.1. Classification of Advanced Therapy Medicinal Products
  • Figure 3.2. Decentralized Manufacturing Process Model
  • Figure 3.3. Types of Cell Therapy Manufacturers
  • Figure 3.4. Cell Therapies: Challenges and Drivers
  • Figure 3.5. Cell Therapies: Potency as a Critical Quality Attribute
  • Figure 3.6. Cell Therapy Manufacturing Supply Chain Model
  • Figure 4.1. Cell Therapy Manufacturers (Industry Players): Distribution by Location of
  • Figure 4.2. Cell Therapy Manufacturers (Industry Players): Distribution by Location of
  • Figure 4.3. Cell Therapy Manufacturers (Industry Players): Distribution by Location of
  • Figure 4.4. Cell Therapy Manufacturers (Industry Players): Distribution by Type of Cells
  • Figure 4.5. Cell Therapy Manufacturers (Industry Players): Distribution by Immune Cells
  • Figure 4.6. Cell Therapy Manufacturers (Industry Players): Distribution by Stem Cells
  • Figure 4.7. Cell Therapy Manufacturers (Industry Players): Distribution by Source of Cells
  • Figure 4.8. Cell Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
  • Figure 4.9. Cell Therapy Manufacturers (Industry Players): Distribution by Type of Cell Culture
  • Figure 4.10. Cell Therapy Manufacturers (Industry Players): Distribution by Purpose of Production
  • Figure 4.11. Cell Therapy Manufacturers (Industry Players): Distribution by Manufacturing
  • Figure 4.12. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Location of Headquarters
  • Figure 4.13. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Location of Manufacturing Facility (Region-wise)
  • Figure 4.14. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Location of Manufacturing Facility (Country-wise)
  • Figure 4.15. Cell Therapy Non-Industry Manufacturers: Distribution by Type of Cells
  • Figure 4.16. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Immune Cells
  • Figure 4.17. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Stem Cells
  • Figure 4.18. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Source of Cells
  • Figure 4.19. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation
  • Figure 4.20. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Type of Cell Culture
  • Figure 4.21. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Purpose of
  • Figure 4.22. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Manufacturing Capabilities / Services
  • Figure 5.1. Number of Facilities Authorized to Manufacture Cell Therapies by Different
  • Figure 6.1. Cell Therapy Manufacturing: Roadmap for the US
  • Figure 6.2. Cell Therapy Manufacturing: Roadmap for the Asia Pacific Economic
  • Figure 7.1. Requirements to Implement Closed Systems in Cell Therapy Manufacturing
  • Figure 7.2. Advantages and Disadvantages of Single-Use Systems
  • Figure 7.3. Cell Therapy Manufacturing: Roadmap for Developing an Automated Device
  • Figure 7.4. Cell Therapy Manufacturing: Comparison of Manual and Automated
  • Figure 7.5. Cell Therapy Manufacturing: Comparison Analysis of Manual and
  • Figure 7.6. Cell Therapy Manufacturing: Comparison of Manual and Automated Processes Based on Annual Cost of Manufacturing
  • Figure 8.1. Cognate BioServices: Service Portfolio
  • Figure 8.2. FUJIFILM Cellular Dynamics: Service Portfolio
  • Figure 8.3. KBI Biopharma: Service Portfolio
  • Figure 8.4. Hitachi Chemical Advanced Therapeutics Solutions: Company Structure
  • Figure 8.5. Hitachi Chemical Advanced Therapeutics Solutions: Service Portfolio
  • Figure 8.6. Waisman Biomanufacturing: Service Portfolio
  • Figure 8.7. Waisman Biomanufacturing: Clinical Products Portfolio
  • Figure 8.8. Waisman Biomanufacturing: Quality Assurance and Control
  • Figure 8.9. Waisman Biomanufacturing: Manufacturing Suites
  • Figure 8.10. Waisman Biomanufacturing: Overview of Manufacturing Services
  • Figure 8.11. BioNTech Innovative Manufacturing Services: Service Portfolio
  • Figure 8.12. Cell and Gene Therapy Catapult: Service Portfolio
  • Figure 8.13. Lonza: Historical Timeline
  • Figure 8.14. Lonza: Important Business Divisions
  • Figure 8.15. Lonza Pharma and Biotech: Service Portfolio
  • Figure 8.16. Lonza: Biological Manufacturing Services
  • Figure 8.17. Lonza: Cell-based Products
  • Figure 8.18. Lonza Netherlands: Service Portfolio
  • Figure 8.19. MaSTherCell: Service Portfolio
  • Figure 8.20. Roslin Cell Therapies: Service Portfolio
  • Figure 8.21. Cell Therapies: Service Portfolio
  • Figure 8.22. Japan Tissue Engineering: Service Portfolio
  • Figure 8.23. MEDINET: Service Portfolio
  • Figure 8.24. Nikon CeLL innovation: Service Portfolio
  • Figure 9.1. Center for Cell and Gene Therapy: Operating Segments
  • Figure 9.2. Center for Cell and Gene Therapy: Service Portfolio
  • Figure 9.3. Center for Cell Manufacturing Ireland: Service Portfolio
  • Figure 9.4. Molecular and Cellular Therapeutics: Service Portfolio
  • Figure 9.5. Newcastle Cellular Therapies Facility: Service Portfolio
  • Figure 11.1. Partnerships: Cumulative Trend by Year (2014-2019)
  • Figure 11.2. Partnerships: Distribution by Type of Partnership Model
  • Figure 11.3. Partnerships: Distribution by Year and Type of Partnership Model (2014-2019)
  • Figure 11.4. Partnerships: Distribution by Type of Cells
  • Figure 11.5. Partnerships: Distribution by Immune Cells
  • Figure 11.6. Partnerships: Distribution by Stem Cells
  • Figure 11.7. Partnerships: Distribution by Scale of Operation
  • Figure 11.8. Partnerships: Distribution by Scale of Operation and Type of Cells
  • Figure 11.9. Partnerships: Continent-wise Distribution
  • Figure 11.10. Partnerships: Country-wise Distribution
  • Figure 11.11. Most Active Players: Distribution by Number of Partnerships
  • Figure 11.12. Heat Map Analysis: Distribution by Most Active Players and Type of Cells
  • Figure 11.13. Acquisitions: Distribution by Year and Type of Cells
  • Figure 11.14. Acquisitions: Continent-wise Distribution
  • Figure 11.15. Acquisitions: Country-wise Distribution
  • Figure 11.16. Acquisitions: Ownership Change Matrix
  • Figure 12.1. Expansions: Cumulative Year-wise Trend, 2014-2019
  • Figure 12.2. Expansions: Distribution by Type of Cells
  • Figure 12.3. Expansions: Distribution by Scale of Operation
  • Figure 12.4. Expansions: Distribution by Purpose of Expansion
  • Figure 12.5. Expansions: Distribution by Location of Facility (Region-wise)
  • Figure 12.6. Expansions: Distribution by Location of Facility (Country-wise)
  • Figure 12.7. Expansions: Distribution by Region and Purpose of Expansion
  • Figure 13.1. Cell Therapy Manufacturing: Installed Global Capacity of Industry Players
  • Figure 13.2. Cell Therapy Manufacturing: Installed Global Capacity of Industry Players
  • Figure 13.3. Cell Therapy Manufacturing Capacity (Industry Players): Distribution by Size
  • Figure 13.4. Cell Therapy Manufacturing Capacity (Industry Players): Distribution by Scale
  • Figure 13.5. Cell Therapy Manufacturing Capacity (Industry Players): Distribution by
  • Figure 13.6. Cell Therapy Manufacturing Capacity (Industry Players): Distribution by Size of Manufacturer (Cleanroom Area)
  • Figure 13.7. Cell Therapy Manufacturing Capacity (Industry Players): Distribution by Scale of Operation (Cleanroom Area)
  • Figure 13.8. Cell Therapy Manufacturing Capacity (Industry Players): Distribution by Location of Manufacturing Facility (Cleanroom Area)
  • Figure 13.9. Cell Therapy Manufacturing: Installed Global Capacity of Non-Industry Players (Number of Cleanrooms)
  • Figure 13.10. Cell Therapy Manufacturing Capacity (Non-Industry Players): Distribution by Scale of Operation (Number of Cleanrooms)
  • Figure 13.11. Cell Therapy Manufacturing Capacity (Non-Industry Players): Distribution by Location of Manufacturing Facility (Number of Cleanrooms)
  • Figure 13.12. Cell Therapy Manufacturing: Installed Global Capacity of Non-Industry Players (Cleanroom Area)
  • Figure 13.13. Cell Therapy Manufacturing Capacity (Non-Industry Players): Distribution by Scale of Operation (Cleanroom Area)
  • Figure 13.14. Cell Therapy Manufacturing Capacity (Non-Industry Players): Distribution by Location of Manufacturing Facility (Cleanroom Area)
  • Figure 14.1. Demand Analysis: Overall Annual Demand for Cell Therapies
  • Figure 14.2. Demand Analysis: Annual Demand for T-cells
  • Figure 14.3. Demand Analysis: Annual Demand for Dendritic and Tumor Cells
  • Figure 14.4. Demand Analysis: Annual Demand for NK Cells
  • Figure 14.5. Demand Analysis: Annual Demand for Stem Cells
  • Figure 14.6. Demand Analysis: Annual Demand for Clinical Scale Operations
  • Figure 14.7. Demand Analysis: Annual Demand for Commercial Scale Operations
  • Figure 14.8. Demand Analysis: Annual Demand for North America
  • Figure 14.9. Demand Analysis: Annual Demand for Europe
  • Figure 14.10. Demand Analysis: Annual Demand for Asia Pacific
  • Figure 15.1. Targeted Therapies: Pricing Model Based on Patient Segment
  • Figure 16.1. Parameters to Assess Complexity of Outsourcing Manufacturing Operations
  • Figure 16.2. Make versus Buy: Decision Making Framework
  • Figure 17.1. Overall Cell Therapy Manufacturing Market, Base Scenario, 2019-2030 (USD
  • Figure 17.2. Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy,
  • Figure 17.3. Cell Therapy Manufacturing Market: Distribution by Source of Cells, 2019-
  • Figure 17.4. Cell Therapy Manufacturing Market: Distribution by Scale of Operation, 2019-2030 (USD Million)
  • Figure 17.5. Cell Therapy Manufacturing Market: Distribution by Purpose of Production, 2019-2030 (USD Million)
  • Figure 17.6. Cell Therapy Manufacturing Market: Geographical Distribution, 2019 and 2030
  • Figure 17.7. Overall Commercial Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2019-2030 (USD Million)
  • Figure 17.8. Commercial Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2019-2030: Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy) (USD Million)
  • Figure 17.9. Commercial Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2019-2030: Distribution by Source of Cells (USD Million)
  • Figure 17.10. Commercial Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2019-2030: Distribution by Regions (USD Million)
  • Figure 17.11. Overall Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2019-2030 (USD Million)
  • Figure 17.12. Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2019-2030: Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy) (USD Million)
  • Figure 17.13. Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2019-2030: Distribution by Source of Cells (USD Million)
  • Figure 17.14. Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2019-2030: Geographical Distribution (USD Million)
  • Figure 17.15. Overall Commercial Scale Manufacturing Market for NK Cell Therapies, Base Scenario, 2019-2030 (USD Million)
  • Figure 17.16. Commercial Scale Manufacturing Market for NK Cell Therapies, Base Scenario, 2019-2030: Distribution by Source of Cells (USD Million)
  • Figure 17.17. Commercial Scale Manufacturing Market for NK Cell Therapies, Base Scenario, 2019-2030: Geographical Distribution (USD Million)
  • Figure 17.18. Overall Commercial Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2019-2030 (USD Million)
  • Figure 17.19. Commercial Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2019-2030: Distribution by Source of Cells (USD Million)
  • Figure 17.20. Commercial Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2019-2030: Geographical Distribution (USD Million)
  • Figure 17.21. Overall Clinical Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2019-2030 (USD Million)
  • Figure 17.22. Clinical Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2019-2030: Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy) (USD Million)
  • Figure 17.23. Clinical Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2019-2030: Distribution by Source of Cells (USD Million)
  • Figure 17.24. Clinical Scale Manufacturing Market for T-cell Therapies, Base Scenario, 2019-2030: Geographical Distribution (USD Million)
  • Figure 17.25. Overall Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2019-2030 (USD Million)
  • Figure 17.26. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2019-2030: Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy) (USD Million)
  • Figure 17.27. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2019-2030: Distribution by Source of Cells (USD Million)
  • Figure 17.28. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base Scenario, 2019-2030: Geographical Distribution (USD Million)
  • Figure 17.29. Overall Clinical Scale Manufacturing Market for NK Cell Therapies, Base Scenario, 2019-2030 (USD Million)
  • Figure 17.30. Clinical Scale Manufacturing Market for NK Cell Therapies, Base Scenario, 2019-2030: Distribution by Source of Cells (USD Million)
  • Figure 17.31. Clinical Scale Manufacturing Market for NK Cell Therapies, Base Scenario, 2019-2030: Geographical Distribution (USD Million)
  • Figure 17.32. Overall Clinical Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2019-2030 (USD Million)
  • Figure 17.33. Clinical Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2019-2030: Distribution by Source of Cells (USD Million)
  • Figure 17.34. Clinical Scale Manufacturing Market for Stem Cell Therapies, Base Scenario, 2019-2030: Distribution by Regions (USD Million)
  • Figure 18.1. Cell Therapy Manufacturers: Grid Analysis by Type of Manufacturer and Scale of Operation
  • Figure 18.2. Cell Therapy Manufacturers: Logo Landscape, Immune Cells
  • Figure 18.3. Cell Therapy Manufacturers: Logo Landscape, Stem Cells
  • Figure 18.4. Cell Therapy Manufacturers (Industry Players): Geographical Distribution by Location of Manufacturing Facility, World Map Representation
  • Figure 18.5. Cell Therapy Manufacturers (Non-Industry Players): Geographical Distribution by Location of Manufacturing Facility, World Map Representation
  • Figure 19.1. Cell Therapy Manufacturing: SWOT Analysis
  • Figure 19.2. Comparison of SWOT Factors: Harvey Ball Analysis
  • Figure 21.1. Survey Insights: Type of Organization
  • Figure 21.2. Survey Insights: Location of Manufacturing Facility
  • Figure 21.3. Survey Insights: Seniority Level of Respondents
  • Figure 21.4. Survey Insights: Type of Cell Therapy
  • Figure 21.5. Survey Insights: Scale of Manufacturing
  • Figure 21.6. Survey Insights: Source of Cells
  • Figure 21.7. Survey Insights: Cell Culture System
  • Figure 21.8. Survey Insights: Fill / Finish Service

List Of Tables

  • Table 3.1. Applications of Cell-based Therapies
  • Table 3.2. Differences between Cell Therapies and Biotechnology Products
  • Table 3.3. Commercialized Cell-based Therapies
  • Table 3.4. Key Cell Therapy Manufacturing Steps
  • Table 3.5. Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
  • Table 4.1. Cell Therapy Manufacturers: List of Industry Players
  • Table 4.2. Cell Therapy Manufacturers: Information on Type of Cells Manufactured
  • Table 4.3. Cell Therapy Manufacturers: Information on Purpose of Production
  • Table 4.4. Cell Therapy Manufacturers: Information on Scale of Operation
  • Table 4.5. Cell Therapy Manufacturers: Information on Source of Cells
  • Table 4.6. Cell Therapy Manufacturers: Information on Type of Cell Culture
  • Table 4.7. Cell Therapy Manufacturers: Information on Type of Manufacturing Capabilities / Services
  • Table 4.8. Cell Therapy Manufacturers: List of Non-Industry Players
  • Table 4.9. Cell Therapy Manufacturers: Information on Type of Cells Manufactured
  • Table 4.10. Cell Therapy Manufacturers: Information on Purpose of Production
  • Table 4.11. Cell Therapy Manufacturers: Information on Scale of Operation
  • Table 4.12. Cell Therapy Manufacturers: Information on Source of Cells
  • Table 4.13. Cell Therapy Manufacturers: Information on Type of Cell Culture
  • Table 4.14. Cell Therapy Manufacturers: Information on Type of Manufacturing Capabilities / Services
  • Table 4.15. Logistics Service Providers for Cell-based Therapies
  • Table 5.1. List of Facilities Approved by Regulators to Manufacture Cell Therapies
  • Table 5.2. Cell Therapy Manufacturing: Regulatory Considerations
  • Table 6.1. Cell Processing: Challenges and Strategies
  • Table 6.2. Cell Preservation, Distribution and Handling: Challenges and Strategies
  • Table 6.3. Process Monitoring and Quality Control: Challenges and Strategies
  • Table 6.4. Standardization and Regulatory Support: Challenges and Strategies
  • Table 6.5. Workforce Development: Challenges and Strategies
  • Table 6.6. Supply Chain and Transport Logistics: Challenges and Strategies
  • Table 7.1. Cell Therapy Manufacturing: List of Service Providers for Automation of Manufacturing Process
  • Table 7.2. Scaling-up Cell Therapy Manufacturing: Switching from Manual to Automated Systems
  • Table 8.1. Cognate BioServices: Company Overview
  • Table 8.2. Cognate BioServices: Overview of Manufacturing Capabilities
  • Table 8.3. Cognate BioServices: Partnerships
  • Table 8.4. Cognate BioServices: Future Outlook
  • Table 8.5. FUJIFILM Cellular Dynamics: Company Overview
  • Table 8.6. FUJIFILM Cellular Dynamics: Overview of Manufacturing Capabilities
  • Table 8.7. FUJIFILM Cellular Dynamics: Partnerships
  • Table 8.8. FUJIFILM Cellular Dynamics: Future Outlook
  • Table 8.9. KBI Biopharma: Company Overview
  • Table 8.10. KBI Biopharma: Overview of Manufacturing Capabilities
  • Table 8.11. KBI Biopharma: Partnerships
  • Table 8.12. KBI Biopharma: Future Outlook
  • Table 8.13. Hitachi Chemical Advanced Therapeutics Solutions: Company Overview
  • Table 8.14. Hitachi Chemical Advanced Therapeutics Solutions: Overview of Manufacturing Capabilities
  • Table 8.15. Hitachi Chemical Advanced Therapeutics Solutions: Partnerships
  • Table 8.16. Hitachi Chemical Advanced Therapeutics Solutions: Future Outlook
  • Table 8.17. Waisman Biomanufacturing: Company Overview
  • Table 8.18. Waisman Biomanufacturing: Overview of Manufacturing Capabilities
  • Table 8.19. Waisman Biomanufacturing: Partnerships
  • Table 8.20. Waisman Biomanufacturing: Future Outlook
  • Table 8.21. BioNTech Innovative Manufacturing Services: Company Overview
  • Table 8.22. BioNTech Innovative Manufacturing Services: Overview of Manufacturing Capabilities
  • Table 8.23. BioNTech Innovative Manufacturing Services: Partnerships
  • Table 8.24. BioNTech Innovative Manufacturing Services: Future Outlook
  • Table 8.25. Cell and Gene Therapy Catapult: Company Overview
  • Table 8.26. Cell and Gene Therapy Catapult: Overview of Manufacturing Capabilities
  • Table 8.27. Cell and Gene Therapy Catapult: Partnerships
  • Table 8.28. Cell and Gene Therapy Catapult: Future Outlook
  • Table 8.29. Lonza: Company Overview
  • Table 8.30. Lonza: Global Manufacturing Sites
  • Table 8.31. Lonza: Overview of Manufacturing Capabilities
  • Table 8.32. Lonza: Partnerships
  • Table 8.33. Lonza: Future Outlook
  • Table 8.34. MaSTherCell: Company Overview
  • Table 8.35. MaSTherCell: Overview of Manufacturing Capabilities
  • Table 8.36. MaSTherCell: Partnerships
  • Table 8.37. MaSTherCell: Future Outlook
  • Table 8.38. Roslin Cell Therapies: Company Overview
  • Table 8.39. Roslin Cell Therapies: Overview of Manufacturing Capabilities
  • Table 8.40. Roslin Cell Therapies: Partnerships
  • Table 8.41. Roslin Cell Therapies: Future Outlook
  • Table 8.42. Cell Therapies: Company Overview
  • Table 8.43. Cell Therapies: Overview of Manufacturing Capabilities
  • Table 8.44. Cell Therapies: Partnerships
  • Table 8.45. Cell Therapies: Future Outlook
  • Table 8.46. Japan Tissue Engineering: Company Overview
  • Table 8.47. Japan Tissue Engineering: Overview of Manufacturing Capabilities
  • Table 8.48. Japan Tissue Engineering: Partnerships
  • Table 8.49. Japan Tissue Engineering: Future Outlook
  • Table 8.50. MEDINET: Company Overview
  • Table 8.51. MEDINET: Overview of Manufacturing Capabilities
  • Table 8.52. MEDINET: Partnerships
  • Table 8.53. MEDINET: Future Outlook
  • Table 8.54. Nikon CeLL innovation: Company Overview
  • Table 8.55. Nikon CeLL innovation: Overview of Manufacturing Capabilities
  • Table 8.56. Nikon CeLL innovation: Partnerships
  • Table 8.57. Nikon CeLL innovation: Future Outlook
  • Table 8.58. WuXi Advanced Therapies: Company Overview
  • Table 8.59. WuXi Advanced Therapies: Overview of Manufacturing Capabilities
  • Table 8.60. WuXi Advanced Therapies: Partnerships
  • Table 8.61. WuXi Advanced Therapies: Future Outlook
  • Table 9.1. Center for Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities
  • Table 9.2. Center for Cell Manufacturing Ireland: Overview of Manufacturing Facilities and Capabilities
  • Table 9.3. Clinical Cell and Vaccine Production Facility: Overview of Manufacturing Facilities and Capabilities
  • Table 9.4. Guy's and St. Thomas GMP Facility: Overview of Manufacturing Facilities and Capabilities
  • Table 9.5. Laboratory of Cell and Gene Medicine: Overview of Manufacturing Facilities and Capabilities
  • Table 9.6. Molecular and Cellular Therapeutics: Overview of Manufacturing Facilities and Capabilities
  • Table 9.7. Newcastle Cellular Therapies Facility: Overview of Manufacturing Facilities and Capabilities
  • Table 9.8. Rayne Cell Therapy Suite: Overview of Manufacturing Facilities and Capabilities
  • Table 9.9. Scottish National Blood Transfusion Services: Overview of Manufacturing Services and Capabilities
  • Table 9.10. Sydney Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities
  • Table 10.1. Cell Therapy Manufacturing: List of Non-Profit Organizations
  • Table 10.2. CellCAN: Overview
  • Table 10.3. Cell Therapy Manufacturing Cooperative Research Center: Overview
  • Table 10.4. National Cell Manufacturing Consortium: Overview
  • Table 10.5. California Institute of Regenerative Medicine: Overview
  • Table 10.6. Cell Therapy Manufacturing: List of Gene and Cell Therapy Societies
  • Table 11.1. Cell Therapy Manufacturing: List of Partnerships
  • Table 11.2. Cell Therapy Manufacturing Partnerships: Distribution by Type of Cells
  • Table 11.3. Cell Therapy Manufacturing Partnerships: Distribution by Scale of Operation
  • Table 11.4. Cell Therapy Manufacturing: List of Acquistions
  • Table 12.1. Cell Therapy Manufacturing: List of Expansions
  • Table 12.2. Cell Therapy Manufacturing Expansions: Distribution by Type of Cells
  • Table 12.3. Cell Therapy Manufacturing Expansions: Distribution by Scale of Operation
  • Table 13.1. Cell Therapy Manufacturing Capacity (Sample Data Set for Industry Players): Average Capacity by Size of Manufacturer (Number of Cleanrooms)
  • Table 13.2. Cell Therapy Manufacturing Capacity (Industry Players): Distribution by Size of Manufacturers (Number of Cleanrooms)
  • Table 13.3. Cell Therapy Manufacturing Capacity (Sample Data Set for Industry Players): Average Capacity by Size of Manufacturer (Cleanroom Area)
  • Table 13.4. Cell Therapy Manufacturing Capacity (Industry Players): Distribution by Size of Manufacturer (Cleanroom Area)
  • Table 13.5. Cell Therapy Manufacturing Capacity for Non-Industry Players: Average Capacity (Number of Cleanrooms)
  • Table 13.6. Cell Therapy Manufacturing Capacity for Non-Industry Players: Average Capacity (Cleanroom Area)
  • Table 15.1. Costs Associated with Manufacturing Stem Cell Therapies
  • Table 15.2. Price of Marketed Gene / Cell Therapies
  • Table 15.3. Price of Marketed Targeted Drugs
  • Table 15.4. T-cell Immunotherapies: Expert Opinions on Pricing
  • Table 15.5. CAR-T Cell Therapies: Reimbursement Landscape
  • Table 17.1. Active Clinical Studies for Autologous Cell Therapies
  • Table 17.2. Active Clinical Studies for Allogeneic Cell Therapies
  • Table 17.3. Active Clinical Studies for Autologous Cell Therapies: Distribution by Patients Enrolled
  • Table 17.4. Active Clinical Studies for Allogeneic Cell Therapies: Distribution by Patients Enrolled
  • Table 20.1. Cell Therapy Manufacturing: Key Takeaways
  • Table 21.1. Survey Insights: Overview of the Participating Organizations
  • Table 21.2. Survey Insights: Seniority Level of Respondents
  • Table 21.3. Survey Insights: Type of Cell Therapy
  • Table 21.4. Survey Insights: Scale of Operation
  • Table 21.5. Survey Insights: Source of Cells
  • Table 21.6. Survey Insights: Cell Culture System
  • Table 21.7. Survey Insights: Fill / Finish Service
  • Table 22.1. Lion TCR: Company Snapshot
  • Table 22.2. Cell Therapies: Company Snapshot
  • Table 22.3. CiMaas: Company Snapshot
  • Table 22.4. Gracell Biotechnologies: Company Snapshot
  • Table 22.5. Glycostem Therapeutics: Company Snapshot
  • Table 22.6. Kadimastem: Company Snapshot
  • Table 22.7. Bio Elpida: Company Snapshot
  • Table 22.8. Center for Commercialization of Cancer Immunotherapy / C3i: Company Snapshot
  • Table 22.9. Waisman Biomanufacturing: Company Snapshot
  • Table 22.10. RoslinCT: Company Snapshot
  • Table 22.11. Yposkesi: Company Snapshot
  • Table 22.12. University of Minnesota: Organization Snapshot
  • Table 23.1. Cell Therapy Manufacturers (Industry Players): Distribution by Location of Headquarters
  • Table 23.2. Cell Therapy Manufacturers (Industry Players): Distribution by Location of Manufacturing Facility (Region-wise)
  • Table 23.3. Cell Therapy Manufacturers (Industry Players): Distribution by Location of Manufacturing Facility (Countru-wise)
  • Table 23.4. Cell Therapy Manufacturers (Industry Players): Distribution by Type of Cells Manufactured
  • Table 23.5. Cell Therapy Manufacturers (Industry Players): Distribution by Immune Cells
  • Table 23.6. Cell Therapy Manufacturers (Industry Players): Distribution by Stem Cells
  • Table 23.7. Cell Therapy Manufacturers (Industry Players): Distribution by Source of Cells
  • Table 23.8. Cell Therapy Manufacturers (Industry Players): Distribution by Scale of Operation
  • Table 23.9. Cell Therapy Manufacturers (Industry Players): Distribution by Type of Cell Culture
  • Table 23.10. Cell Therapy Manufacturers (Industry Players): Distribution by Purpose of Production
  • Table 23.11. Cell Therapy Manufacturers (Industry Players): Distribution by Manufacturing Capabilities / Services
  • Table 23.12. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Location of Headquarters
  • Table 23.13. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Location of Manufacturing Facility (Region-wise)
  • Table 23.14. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Location of Manufacturing Facility (Country-wise)
  • Table 23.15. Cell Therapy Non-Industry Manufacturers: Distribution by Type of Cells Manufactured
  • Table 23.16. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Immune Cells
  • Table 23.17. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Stem Cells
  • Table 23.18. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Source of Cells
  • Table 23.19. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Scale of Operation
  • Table 23.20. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Type of Cell Culture
  • Table 23.21. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Purpose of Production
  • Table 23.22. Cell Therapy Manufacturers (Non-Industry Players): Distribution by Manufacturing Capabilities / Services
  • Table 23.24. Cell Therapy Manufacturing: Distribution of Manufacturing Facilities by Regulatory Authorities
  • Table 23.25. Partnerships: Cumulative Trend by Year (20123-2019)
  • Table 23.26. Partnerships: Distribution by Type of Partnership Model
  • Table 23.27. Partnerships: Distribution by Year and Type of Partnership Model (20123-2019)
  • Table 23.28. Partnerships: Distribution by Type of Cells
  • Table 23.29. Partnerships: Distribution by Immune Cells
  • Table 23.30. Partnerships: Distribution by Stem Cells
  • Table 23.31. Partnerships: Distribution by Scale of Operation
  • Table 23.32. Partnerships: Distribution by Scale of Operation and Type of Cells
  • Table 23.33. Partnerships: Continent-wise Distribution
  • Table 23.34. Partnerships: Country-wise Distribution
  • Table 23.35. Most Active Players: Distribution by Number of Partnerships
  • Table 23.36. Acquisitions: Distribution by Year and Type of Cells
  • Table 23.37. Acquisitions: Continent-wise Distribution
  • Table 23.38. Acquisitions: Country-wise Distribution
  • Table 23.39. Acquisitions: Ownership Change Matrix
  • Table 23.40. Expansions: Cumulative Year-wise Trend, 20123-2019
  • Table 23.41. Expansions: Distribution by Type of Cells
  • Table 23.42. Expansions: Distribution by Scale of Operation
  • Table 23.43. Expansions: Distribution by Purpose of Expansion
  • Table 23.44. Expansions: Distribution by Location of Facility (Region-wise)
  • Table 23.45. Expansions: Distribution by Location of Facility (Country-wise)
  • Table 23.46. Expansions: Distribution by Region and Purpose of Expansion
  • Table 23.47. Cell Therapy Manufacturing Capacity (Industry Players): Distribution by Size of Manufacturer (Number of Cleanrooms)
  • Table 23.48. Cell Therapy Manufacturing Capacity (Industry Players): Distribution by Scale of Operation (Number of Cleanrooms)
  • Table 23.49. Cell Therapy Manufacturing Capacity (Industry Players): Distribution by Location of Manufacturing Facility (Number of Cleanrooms)
  • Table 23.50. Cell Therapy Manufacturing Capacity (Industry Players): Distribution by Size of Manufacturer (Cleanroom Area)
  • Table 23.51. Cell Therapy Manufacturing Capacity (Industry Players): Distribution by Scale of Operation (Cleanroom Area)
  • Table 23.52. Cell Therapy Manufacturing Capacity (Non-Industry Players): Distribution by Scale of Operation (Number of Cleanrooms)
  • Table 23.53. Cell Therapy Manufacturing Capacity (Non-Industry Players): Distribution by Location of Manufacturing Facility (Number of Cleanrooms)
  • Table 23.54. Cell Therapy Manufacturing Capacity (Non-Industry Players): Distribution by Scale of Operation (Cleanroom Area)
  • Table 23.55. Cell Therapy Manufacturing Capacity (Non-Industry Players): Distribution by Location of Manufacturing Facility (Cleanroom Area)
  • Table 23.56. Demand Analysis: Overall Annual Demand for Cell Therapies
  • Table 23.57. Demand Analysis: Annual Demand for T-cells
  • Table 23.58. Demand Analysis: Annual Demand for Dendritic and Tumor Cells
  • Table 23.59. Demand Analysis: Annual Demand for NK Cells
  • Table 23.60. Demand Analysis: Annual Demand for Stem Cells
  • Table 23.61. Demand Analysis: Annual Demand for Clinical Scale Operations
  • Table 23.62. Demand Analysis: Annual Demand for Commercial Scale Operations
  • Table 23.63. Demand Analysis: Annual Demand for North America
  • Table 23.64. Demand Analysis: Annual Demand for Europe
  • Table 23.65. Demand Analysis: Annual Demand for Asia Pacific
  • Table 23.66. Overall Cell Therapy Manufacturing Market, Base, Conservative and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 23.67. Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy, 2019-2030 (USD Million)
  • Table 23.68. Cell Therapy Manufacturing Market: Distribution by Source of Cells, 2019-2030 (USD Million)
  • Table 23.69. Cell Therapy Manufacturing Market: Distribution by Scale of Operation, 2019-2030 (USD Million)
  • Table 23.70. Cell Therapy Manufacturing Market: Distribution by Purpose of Production, 2019-2030 (USD Million)
  • Table 23.71. Cell Therapy Manufacturing Market: Geographical Distribution, 2019 and 2030
  • Table 23.72. Overall Commercial Scale Manufacturing Market for T-cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 23.73. Commercial Scale Manufacturing Market for T-cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy) (USD Million)
  • Table 23.74. Commercial Scale Manufacturing Market for T-cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Distribution by Source of Cells (USD Million)
  • Table 23.75. Commercial Scale Manufacturing Market for T-cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Distribution by Regions (USD Million)
  • Table 23.76. Overall Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 23.77. Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy) (USD Million)
  • Table 23.78. Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Distribution by Source of Cells (USD Million)
  • Table 23.79. Commercial Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Geographical Distribution (USD Million)
  • Table 23.80. Overall Commercial Scale Manufacturing Market for NK Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 23.81. Commercial Scale Manufacturing Market for NK Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Distribution by Source of Cells (USD Million)
  • Table 23.82. Commercial Scale Manufacturing Market for NK Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Geographical Distribution (USD Million)
  • Table 23.83. Overall Commercial Scale Manufacturing Market for Stem Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 23.84. Commercial Scale Manufacturing Market for Stem Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Distribution by Source of Cells (USD Million)
  • Table 23.85. Commercial Scale Manufacturing Market for Stem Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Geographical Distribution (USD Million)
  • Table 23.86. Overall Clinical Scale Manufacturing Market for T-cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 23.87. Clinical Scale Manufacturing Market for T-cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Distribution by Type of Therapy (CAR-T Therapy, TCR Therapy, TIL Therapy) (USD Million)
  • Table 23.88. Clinical Scale Manufacturing Market for T-cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Distribution by Source of Cells (USD Million)
  • Table 23.89. Clinical Scale Manufacturing Market for T-cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Geographical Distribution (USD Million)
  • Table 23.90. Overall Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 23.91. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Distribution by Type of Therapy (Dendritic Cell Therapy, Tumor Cell Therapy) (USD Million)
  • Table 23.92. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Distribution by Source of Cells (USD Million)
  • Table 23.93. Clinical Scale Manufacturing Market for Dendritic Cell and Tumor Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Geographical Distribution (USD Million)
  • Table 23.94. Overall Clinical Scale Manufacturing Market for NK Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 23.95. Clinical Scale Manufacturing Market for NK Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Distribution by Source of Cells (USD Million)
  • Table 23.96. Clinical Scale Manufacturing Market for NK Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Geographical Distribution (USD Million)
  • Table 23.97. Overall Clinical Scale Manufacturing Market for Stem Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030 (USD Million)
  • Table 23.98. Clinical Scale Manufacturing Market for Stem Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Distribution by Source of Cells (USD Million)
  • Table 23.99. Clinical Scale Manufacturing Market for Stem Cell Therapies, Base, Conservative and Optimistic Scenarios, 2019-2030: Distribution by Regions (USD Million)
  • Table 23.100. Survey Insights: Distribution by Type of Organization
  • Table 23.101. Survey Insights: Distribution by Location of Manufacturing Facility
  • Table 23.102. Survey Insights: Distribution by Seniority Level of Respondents
  • Table 23.103. Survey Insights: Distribution by Type of Cell Therapy
  • Table 23.104. Survey Insights: Distribution by Scale of Manufacturing
  • Table 23.105. Survey Insights: Distribution by Source of Cells
  • Table 23.106. Survey Insights: Distribution by Cell Culture System
  • Table 23.107. Survey Insights: Distribution by Fill / Finish Service

Listed Companies

  • The following companies / institutes / government bodies and organizations have been mentioned in this report.
  • 3P Biopharmaceuticals
  • A2 Healthcare
  • Accellta
  • Acerta Pharma
  • Adaptimmune
  • Adva Biotechnology
  • Advanced Cell Therapy Laboratory, Yale School of Medicine
  • Advanced Regenerative Manufacturing Institute
  • Advent Bioservices
  • Agios Pharmaceuticals
  • Ajinomoto
  • Akron Biotech
  • Alberta Cell Therapy Manufacturing, University of Alberta
  • Allele Biotechnology & Pharmaceuticals
  • Alliance for Regenerative Medicine
  • AlloSource
  • Altor BioScience
  • American Productivity & Quality Center
  • American Society of Gene and Cell Therapy
  • American Society of Mechanical Engineers
  • Amgen
  • Amsterdam Biotherapeutics Unit
  • Andalusian Initiative for Advanced Therapies
  • Angiocrine Bioscience
  • Anterogen
  • Aokai (Suzhou) Biomedical
  • apceth Biopharma
  • Argos Therapeutics
  • ARIAD Pharmaceuticals
  • Asahi Glass Company
  • Asterias Biotherapeutics
  • AstraZeneca
  • Asymptote
  • Atara Biotherapeutics
  • Athersys
  • Atlantic Bio GMP
  • ATVIO Biotechnology
  • Australasian Gene and Cell Therapy Society
  • Austrian Network for Gene Therapy
  • Autolus
  • Azellon Cell Therapeutics
  • Bavarian Nordic
  • Bayer
  • Be The Match BioTherapies
  • Bellicum Pharmaceuticals
  • Berkeley Lights
  • Bio Elpida
  • BioCision
  • Bioinova
  • BioLife Solutions
  • Biological and Cellular GMP Manufacturing Facility, City of Hope
  • biologistex CCM
  • BioNTech Innovative Manufacturing Services
  • Biosafe Group
  • bluebird bio
  • Boehringer Ingelheim
  • Bone Therapeutics
  • Brammer Bio
  • Bristol-Myers Squibb
  • British Society for Gene and Cell Therapy
  • Caladrius Biosciences
  • California Institute of Regenerative Medicine
  • Cancer Research UK
  • Capricor Therapeutics
  • CardioCell
  • Celgene
  • Cell and Gene Therapy Catapult
  • Cell Manipulation Core, Dana-Farber / Harvard Cancer Center
  • Cell Medica
  • Cell Tech Pharmed
  • Cell Therapies
  • Cell Therapy and Regenerative Medicine, University of Utah
  • Cell Therapy Facility, UMC Utrecht
  • Cell Therapy Manufacturing Cooperative Research Center
  • Cell Therapy Suite, University of Birmingham
  • Cellab
  • CellCAN
  • Cellectis
  • CELLforCURE
  • Cellin Technologies
  • Cells Cure Foundation
  • Cells for Sight Stem Cell Therapy Research Unit, University College London
  • Cellular Biomedicine Group
  • Cellular Therapeutics
  • Cellular Therapy Core, University of Texas
  • Cellular Therapy Integrated Services, Case Western Reserve University
  • Celyad
  • Censo Biotechnologies
  • Center for Biomedical Engineering and Advanced Manufacturing, McMaster University
  • Center for Cell and Gene Therapy, Baylor College of Medicine
  • Center for Gene and Cell Processing, Takara Bio
  • Center for International Blood and Marrow Transplant Research
  • Centre for Biological Engineering, Loughborough University
  • Centre for Cell and Vector Production
  • Centre for Cell Manufacturing Ireland, NUI Galway
  • Centre for Commercialization of Regenerative Medicine
  • Centre for Stem Cell Research
  • Centre for Commercialization of Cancer Immunotherapy (C3i)
  • Centre multidisciplinaire de développement du génie tissulaire
  • Centre of Genomics and Policy, McGill University
  • Cesca Therapeutics
  • Chemometec
  • Chiesi Farmaceutici
  • Children's Medical Research Institute
  • Children's GMP, St. Jude Children's Research Hospital
  • China Life Health Industry Group
  • China Regenerative Medicine International
  • CiMaas
  • City of Hope Alpha Clinic for Cell Therapy
  • Clinical Biomanufacturing Facility, University of Oxford
  • Clinical Cell and Vaccine Production Facility
  • Clinical Research Facility, South London and Maudsley
  • Closed Cell Systems
  • Cognate BioServices
  • Commonwealth Scientific and Industrial Research Organization
  • Cook MyoSite
  • CRISPR Therapeutics
  • Cryoport
  • Cryosite
  • CureCell
  • Cynata Therapeutics
  • Cytonome
  • Cytori Therapeutics
  • CyTuVax
  • DanDrit Biotech
  • DCPrime
  • Dendreon
  • DiscGenics
  • Eli Lilly
  • EMERCell
  • Emory Personalized Immunotherapy Core
  • European Bank for induced pluripotent Stem Cells
  • European Society of Gene and Cell Therapy
  • Federal Economic Development Agency for Southern Ontario
  • Ferrologix
  • Fibrocell
  • Finnish Gene Therapy Society
  • Fisher BioServices
  • FloDesign Sonics
  • Fortuna Fix
  • Fosun Pharma
  • Foundation for the Accreditation of Cellular Therapy
  • Foundation of Croatian Association for Regenerative Medicine and Stem Cell Therapy
  • Fraunhofer Institute for Cell Therapy and Immunology IZI
  • French Society of Cellular and Gene Therapy
  • Froceth
  • FUJIFILM Cellular Dynamics
  • Gamida Cell
  • Gates Biomanufacturing Facility
  • GC Cell
  • GE Healthcare
  • GenCure
  • Gene and Cell Therapy Lab, Institute of Translational Health Sciences
  • Genentech
  • Georgia Institute of Technology
  • Georgia Research Alliance
  • German Gene Therapy Society
  • Gilead Sciences
  • GlaxoSmithKline
  • Glycostem Therapeutics
  • GPB Scientific
  • Gradalis
  • Great Ormond Street Hospital Cellular Therapy Laboratories, University College London
  • Guy's and St Thomas' Facility
  • Haematological Sciences, Institute of Cellular Medicine
  • Harvard University Stem Cell Institute
  • Health Sciences Authority
  • Hielscher Ultrasonics
  • Histocell
  • Hitachi Chemical Advanced Therapeutics Solutions
  • Holostem Terapie Avanzate
  • Hospital of University of Pennsylvania
  • Houston Methodist Hospital Foundation
  • Houston Methodist Institute of Technology, Innovation and Education
  • Houston Methodist Research Institute
  • Human Islet and Cellular Transplant Facility
  • Human Stem Cells Institute
  • Immatics Biotechnologies
  • ImmunoCellular Therapeutics
  • Immunocore
  • Immunovative Therapies
  • IncoCell Tianjin
  • Innovate UK
  • Innovative Cellular Therapeutics
  • IntelliCell BioSciences
  • Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami
  • International Cellular Medicine Society
  • International Society for Cancer Gene Therapy
  • International Society for Cellular Therapy
  • International Society for Stem Cell Research
  • International Stem Cell Corporation
  • Invetech
  • Iovance Biotherapeutics
  • IQVIA Stem Cell Center
  • Irish Society for Gene and Cell Therapy
  • Irish Stem Cell Foundation
  • Israeli Society for Gene and Cell Therapy
  • Isto Biologics
  • Japan Society for Gene Therapy
  • Japan Tissue Engineering
  • Jazz Pharmaceuticals
  • JCR Pharmaceuticals
  • John Goldmann Centre for Cellular Therapy, Imperial College London
  • Juno Therapeutics
  • JW CreaGene
  • Kawasaki Heavy Industries
  • KBI Biopharma
  • Kiadis Pharma
  • Kids Research Institute
  • Kite Pharma
  • KMC Systems
  • Kolon TissueGene
  • Korean Society of Gene and Cell Therapy
  • Laboratory for Cell and Gene Medicine, University of Stanford
  • Lexicon Pharmaceuticals
  • Lion TCR
  • Lonza
  • Maisonneuve-Rosemont Hospital
  • Marken
  • MaSTherCell
  • Mayo Clinic Center for Regenerative Medicine
  • MedCision
  • Medigene
  • MEDINET
  • MEDIPOST
  • Medistem Panama (Stem Cell Institute)
  • MedPost
  • MedStar Georgetown University Hospital
  • Merck
  • Mesoblast
  • Michael Smith Laboratories, University of British Columbia
  • Millennium Pharmaceuticals
  • Millipore Sigma
  • Miltenyi Biotec
  • MNX Global Logistics
  • Moffitt Cancer Center
  • Molecular and Cellular Therapeutics, University of Minnesota
  • MolMed
  • Mustang Bio
  • Nantes University Hospital
  • National Cell Manufacturing Consortium
  • National Centre for Biomedical Engineering Sciences
  • National Eye Institute
  • National Gene Vector Laboratory
  • National Institute of Health Research
  • National Institute of Standards and Technologies
  • National Stem Cell Foundation
  • National Stem Cell Foundation of Australia
  • Neon Therapeutics
  • Netherlands Cancer Institute
  • Networks of Centres of Excellence
  • Neuralstem
  • NewLink Genetics
  • NHSBT Blood and Transplant, Birmingham
  • Nikon
  • Nikon CeLL innovation
  • Nohla Therapeutics
  • Northwest Biotherapeutics
  • Norwegian Radium Hospital
  • Novadip
  • Novartis
  • NuVasive
  • Octane Medical Group
  • Oncobiomed
  • Ontario Institute of Regenerative Medicine
  • Onyx Pharmaceuticals
  • Opexa Therapeutics
  • Orchard Therapeutics
  • Orgenesis
  • Orthofix
  • Ospedale Pediatrico Bambino Gesù
  • Ottawa Hospital Research Institute, University of Ottawa
  • Oxford BioMedica
  • Oxford MEStar
  • Pall
  • PAREXEL
  • PCI Services
  • PCT Cell Therapy Services
  • The Peter Couche Foundation
  • Peter MacCallum Cancer Centre
  • Pfizer
  • PharmaBio
  • PharmaCell
  • Pharmicell
  • Pluristem Therapeutics
  • Praxis Pharmaceutical
  • Production Assistance for Cellular Therapies
  • Promethera Biosciences
  • Provia Laboratories
  • Puma Biotechnology
  • Q-GEN Cell Therapeutics, QIMR Berghofer Medical Research Institute
  • Rayne Cell Therapy Suite, King's College London
  • Regenerative Medicine Foundation
  • Regenerative Medicine Institute
  • Regenesys
  • Regeneus
  • Reliance Life Sciences
  • ReNeuron
  • RepliCel
  • Research and Development Center for Cell Therapy, Foundation for Biomedical Research and Innovation
  • Riyadh Pharma
  • Robertson Clinical and Translational Cell Therapy, Duke University
  • Roche Diagnostics
  • RoosterBio
  • Roslin Cells
  • Roswell Park Cancer Institute
  • Royal Free Hospital, Centre for Cell and Gene Tissue Therapeutics
  • Royal Prince Alfred Hospital
  • Saint-Gobain
  • SanBio
  • Sartorius Stedim Biotech
  • SAVSU Technologies
  • Scinogy
  • Scottish Centre for Regenerative Medicine
  • Scottish National Blood Transfusion Service Cellular Therapy Facility
  • Servier
  • Shanghai Sunway Biotech
  • Shenzhen Sibiono GeneTech
  • SHIBUYA
  • Sistemic
  • Smilow Center for Translational Research
  • Smith & Nephew
  • SOTIO
  • Spanish Society for Gene and Cell Therapy
  • Spark Therapeutics
  • Stage Cell Therapeutics
  • Stanford Children's Health, Stanford Health Care
  • Stanford Medicine
  • Stemedica Cell Technologies
  • Sumitomo Dainippon Pharma
  • Swedish Society for Gene and Cell Therapy
  • Sydney Cell and Gene Therapy
  • Syngen Biotech
  • Takeda Pharmaceutical
  • TAP Biosystems
  • TargetAMD
  • TC BioPharm
  • T-Cell Factory
  • Terumo
  • Terumo BCT
  • TESARO
  • Texas Children's Hospital
  • Texas Medical Center
  • The Children's Hospital at Westmead
  • The Elisa Linton Center for Rare Disease Therapies
  • The Michael G. Harris Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center
  • The Netherlands Society of Gene and Cell Therapy
  • The New York Stem Cell Foundation
  • The Ottawa Hospital Research Institute
  • The Philip S Orsino Facility for Cell Therapy, Princess Margaret Hospital
  • The University of Texas Health Science Center
  • Therapeutic Cell Production Core, Seattle Children's Hospital
  • Thermo Fisher Scientific
  • ThermoGenesis
  • TiGenix
  • Tokyo Electron
  • TrakCel
  • Trinity Partners
  • Turkish Society for Gene and Cell Therapy
  • TVAX Biomedical
  • TxCell
  • Tyne Hospitals NHS Foundation Trust
  • UC Davis GMP Laboratory
  • UCLA Human Gene and Cell Therapy
  • UCLA-UCI Alpha Stem Cell Clinic
  • UK Stem Cell Foundation
  • University Hospital Basel
  • University Medical Center Groningen
  • University of California
  • University of Leeds
  • University of Manchester
  • University of Newcastle
  • University of North Carolina Lineberger Comprehensive Cancer Center
  • University of Tennessee
  • University of Wisconsin-Madison
  • Upstate Stem Cell cGMP Facility, University of Rochester
  • Vaccinogen
  • Valeant Pharmaceuticals
  • Vecura, Karolinska University Hospital
  • Vericel
  • Vineti
  • Vitruvian Networks
  • VivaBioCell
  • Waisman Biomanufacturing
  • Westmead Hospital
  • Westmead Millennium Institute
  • World Courier
  • WuXi Advanced Therapies
  • WuXi AppTec
  • Wyeth
  • Xellbiogene
  • Yposkesi
  • Zelluna Immunotherapy

Segmentation

The USD 10+ billion (by 2030) financial opportunity within the cell therapy manufacturing market has been analyzed across the following segments:

  • Type of therapy
    • T-cell therapies (CAR-T therapies, TCR therapies, TIL therapies)
    • Dendritic cell therapies
    • Tumor cell therapies
    • Stem cell therapies
  • Source of cells
    • Autologous
    • Allogeneic
  • Scale of operation
    • Clinical
    • Commercial
  • Purpose of manufacturing
    • Contract manufacturing
    • In-house manufacturing
  • Key geographical regions
    • North America
    • Europe
    • Asia Pacific
    • Rest of the world